Related references
Note: Only part of the references are listed.Histone deacetylase inhibitors in lymphoma and solid malignancies
Walid Rasheed et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2008)
Epigenetic targets in hematological malignancies: Combination therapies with HDACis and demethylating agents
Mark Bishton et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2007)
Regulation of the expression of MHC class I-related chain A, B (MICA, MICB) via chromatin remodeling and its impact on the susceptibility of leukemic cells to the cytotoxicity of NKG2D-expressing cells
N. Kato et al.
LEUKEMIA (2007)
A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors
M. Candelaria et al.
ANNALS OF ONCOLOGY (2007)
Valproic acid (VPA) in patients with refractory advanced cancer:: a dose escalating phase I clinical trial
A. Atmaca et al.
BRITISH JOURNAL OF CANCER (2007)
Phase I and pharmacokinetic study of vorinostat, A histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies
Suresh S. Ramalingam et al.
CLINICAL CANCER RESEARCH (2007)
Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors:: A clinical and translational study
Pamela Muenster et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Histone deacetylase inhibitors in cancer therapy
Walid K. Rasheed et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2007)
A Proof-Of-Principle Study of Epigenetic Therapy Added to Neoadjuvant Doxorubicin Cyclophosphamide for Locally Advanced Breast Cancer
Claudia Arce et al.
PLOS ONE (2006)
Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous interleukin-2 and interferon-α2b in metastatic melanoma
E Bajetta et al.
ANNALS OF ONCOLOGY (2006)
Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer
S Minucci et al.
NATURE REVIEWS CANCER (2006)
New method to detect histone acetylation levels by flow cytometry
S Ronzoni et al.
CYTOMETRY PART A (2005)
Histone deacetylase inhibitors and malignant melanoma
GM Boyle et al.
PIGMENT CELL RESEARCH (2005)
A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia
JC Byrd et al.
BLOOD (2005)
Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway
A Insinga et al.
NATURE MEDICINE (2005)
Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma:: A phase III study
MF Avril et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Modulation of pro- and anti-apoptotic factors in human melanoma cells exposed to histone deacetylase inhibitors
F Facchetti et al.
APOPTOSIS (2004)
Apoptosis and melanoma chemoresistance
MS Soengas et al.
ONCOGENE (2003)
Sequential biochemotherapy versus chemotherapy for metastatic melanoma: Results from a phase III randomized trial
O Eton et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Cisplatin, dacarbazine with or without subcutaneous interleukin-2, and interferon alfa-2b in advanced melanoma outpatients: Results from an Italian Multicenter phase III Randomized Clinical Trial
R Ridolfi et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells
M Göttlicher et al.
EMBO JOURNAL (2001)
Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report
RL Piekarz et al.
BLOOD (2001)
Nitroso-urea-cisplatin-based chemotherapy associated with valproate: Increase of haematologic toxicity
V Bourg et al.
ANNALS OF ONCOLOGY (2001)
Single-agent DTIC versus combination chemotherapy with or without immunotherapy in metastatic melanoma: a meta-analysis of 3273 patients from 20 randomized trials
M Huncharek et al.
MELANOMA RESEARCH (2001)
Inactivation of the apoptosis effector Apaf-1 in malignant melanoma
MS Soengas et al.
NATURE (2001)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
Histone deacetylase inhibitors: Inducers of differentiation or apoptosis of transformed cells
PA Marks et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Share Paper
